SV2A and myeloid sarcoma: A clinical study assessing the utility of 18F-SDM-8 in a cohort of 30 MS patients (NCT04634994) has been initiated, and its results could shed light on the utility of SV2A PET as a biomarker for synaptic pathology in MS.